Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept Pharmacokinetics and Efficacy in Chinese SLE Patients
NCT05247203Phase 1Completed
- Sponsor
- RemeGen
- Start
- May 2022
- Primary completion
- Oct 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of telitacicept in systemic lupus erythematosus (SLE), sponsored by RemeGen. Primary endpoints: Peak Plasma Concentration, Time to Reach Peak Concentration and 3 more. Started May 2022; status: completed.
02
Drugs
telitacicept
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05247203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05247203.